Studies in experimental models of chronic rejection: use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of graft vascular disease and obliterative bronchiolitis.
Morris
R E
RE
Department of Cardiothoracic Surgery, Stanford University School of Medicine, California 94305-5247, USA.
Huang
X
X
Gregory
C R
CR
Billingham
M E
ME
Rowan
R
R
Shorthouse
R
R
Berry
G J
GJ
D000818:Animals; D001989:Bronchiolitis Obliterans / Q000517:prevention & control*; D016572:Cyclosporine / Q000627:therapeutic use; D006083:Graft Occlusion, Vascular / Q000473:pathology / Q000517:prevention & control*; D016027:Heart Transplantation / Q000276:immunology* / Q000473:pathology; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007555:Isoxazoles / Q000627:therapeutic use; D000077339:Leflunomide; D011090:Polyenes / Q000627:therapeutic use; D051381:Rats; D011914:Rats, Inbred BN; D011917:Rats, Inbred Lew; D020123:Sirolimus; D017539:Tunica Intima / Q000473:pathology
D007166:Immunosuppressive Agents; D007555:Isoxazoles; D011090:Polyenes; D016572:Cyclosporine; D000077339:Leflunomide; D020123:Sirolimus